Barclays reinstated coverage of Waters (WAT) with an Overweight rating and $400 price target after the company acquired Becton Dickinson’s LifeSciences Bioprocessing segment.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT: